TENELIGLIPTIN

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category UNKNOWN
ATC A10BH08
UNII 28ZHI4CF9C

Structure

InChI Key WGRQANOPCQRCME-PMACEKPBSA-N
Smiles Cc1cc(N2CCN([C@@H]3CN[C@H](C(=O)N4CCSC4)C3)CC2)n(-c2ccccc2)n1
InChI
InChI=1S/C22H30N6OS/c1-17-13-21(28(24-17)18-5-3-2-4-6-18)26-9-7-25(8-10-26)19-14-20(23-15-19)22(29)27-11-12-30-16-27/h2-6,13,19-20,23H,7-12,14-16H2,1H3/t19-,20-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C22H30N6OS
Molecular Weight 426.59
AlogP 1.57
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 4.0
Polar Surface Area 56.64
Molecular species BASE
Aromatic Rings 2.0
Heavy Atoms 30.0

Bioactivity

Mechanism of Action Action Reference
Dipeptidyl peptidase IV inhibitor INHIBITOR Other Other PubMed
Protein: Dipeptidyl peptidase IV
Description: Dipeptidyl peptidase 4
Organism : Homo sapiens
P27487 ENSG00000197635
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Protease Serine protease Serine protease SC clan Serine protease S9B subfamily
- 0 0-12 - -
Assay Description Organism Bioactivity Reference
Inhibition of DPP4 in human plasma using GLY-Pro-MCA as substrate after 60 mins by fluorescence assay Homo sapiens 0.37 nM
Inhibition of DPP4 in rat plasma using GLY-Pro-MCA as substrate after 60 mins by fluorescence assay Rattus norvegicus 0.29 nM
Ex vivo inhibition of DDP4 in Wistar rat plasma using GLY-Pro-MCA as substrate at 3 umol/kg, po after 0.5 hrs by fluorescence assay Rattus norvegicus 94.8 %
Ex vivo inhibition of DDP4 in Wistar rat plasma using GLY-Pro-MCA as substrate at 3 umol/kg, po after 9 hrs by fluorescence assay Rattus norvegicus 78.3 %
Inhibition of human DPP8 using GLY-Pro-MCA as substrate after 30 mins by cell-based fluorescence assay Homo sapiens 260.0 nM
Inhibition of human DPP9 using GLY-Pro-MCA as substrate after 30 mins by cell-based fluorescence assay Homo sapiens 540.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 8.14 %
Binding affinity to human recombinant DPP4 (39 to 766 residues) by surface plasmon resonance analysis Homo sapiens 0.41 nM
Binding affinity to human recombinant DPP4 (39 to 766 residues) at 5 uM by isothermal titration calorimetry Homo sapiens 11.9 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 7.31 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 15.28 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.01 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.07 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.01 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.07 %

Cross References

Resources Reference
ChEBI 136042
ChEMBL CHEMBL2147777
DrugBank DB11950
DrugCentral 4895
FDA SRS 28ZHI4CF9C
Guide to Pharmacology 9906
PDB M51
PubChem 11949652
SureChEMBL SCHEMBL161778
ZINC ZINC000036520254
CONTENTS